Benzinga | Jun 11, 2021 08:43AM EDT

Baird Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $240

Baird analyst Brian Skorney maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and lowers the price target from $252 to $240.